Search

Your search keyword '"Krex, Dietmar"' showing total 542 results
Start Over Author "Krex, Dietmar"
542 results on '"Krex, Dietmar"'

51. Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas

Author

Krex, Dietmar, primary, Bartmann, Paula, additional, Lachmann, Doris, additional, Hagstotz, Alexander, additional, Jugel, Willi, additional, Schneiderman, Rosa, additional, Gotlib, Karnit, additional, Porat, Yaara, additional, Robel, Katja, additional, Temme, Achim, additional, Giladi, Moshe, additional, and Michen, Susanne, additional

Published
2023
Full Text
View/download PDF

52. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.

Author

Liau, Linda M, Liau, Linda M, Ashkan, Keyoumars, Brem, Steven, Campian, Jian L, Trusheim, John E, Iwamoto, Fabio M, Tran, David D, Ansstas, George, Cobbs, Charles S, Heth, Jason A, Salacz, Michael E, D'Andre, Stacy, Aiken, Robert D, Moshel, Yaron A, Nam, Joo Y, Pillainayagam, Clement P, Wagner, Stephanie A, Walter, Kevin A, Chaudhary, Rekha, Goldlust, Samuel A, Lee, Ian Y, Bota, Daniela A, Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven, Brenner, Andrew J, Ewend, Matthew G, Khagi, Simon, Lovick, Darren S, Portnow, Jana, Kim, Lyndon, Loudon, William G, Martinez, Nina L, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Giglio, Pierre, Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott M, Lutzky, Jose, Meisel, Hans-Jörg, Nadji-Ohl, Minou, Sanchin, Lhagva, Sloan, Andrew, Taylor, Lynne P, Wu, Julian K, Dunbar, Erin M, Etame, Arnold B, Kesari, Santosh, Mathieu, David, Piccioni, David E, Baskin, David S, Lacroix, Michel, May, Sven-Axel, New, Pamela Z, Pluard, Timothy J, Toms, Steven A, Tse, Victor, Peak, Scott, Villano, John L, Battiste, James D, Mulholland, Paul J, Pearlman, Michael L, Petrecca, Kevin, Schulder, Michael, Prins, Robert M, Boynton, Alton L, Bosch, Marnix L, Liau, Linda M, Liau, Linda M, Ashkan, Keyoumars, Brem, Steven, Campian, Jian L, Trusheim, John E, Iwamoto, Fabio M, Tran, David D, Ansstas, George, Cobbs, Charles S, Heth, Jason A, Salacz, Michael E, D'Andre, Stacy, Aiken, Robert D, Moshel, Yaron A, Nam, Joo Y, Pillainayagam, Clement P, Wagner, Stephanie A, Walter, Kevin A, Chaudhary, Rekha, Goldlust, Samuel A, Lee, Ian Y, Bota, Daniela A, Elinzano, Heinrich, Grewal, Jai, Lillehei, Kevin, Mikkelsen, Tom, Walbert, Tobias, Abram, Steven, Brenner, Andrew J, Ewend, Matthew G, Khagi, Simon, Lovick, Darren S, Portnow, Jana, Kim, Lyndon, Loudon, William G, Martinez, Nina L, Thompson, Reid C, Avigan, David E, Fink, Karen L, Geoffroy, Francois J, Giglio, Pierre, Gligich, Oleg, Krex, Dietmar, Lindhorst, Scott M, Lutzky, Jose, Meisel, Hans-Jörg, Nadji-Ohl, Minou, Sanchin, Lhagva, Sloan, Andrew, Taylor, Lynne P, Wu, Julian K, Dunbar, Erin M, Etame, Arnold B, Kesari, Santosh, Mathieu, David, Piccioni, David E, Baskin, David S, Lacroix, Michel, May, Sven-Axel, New, Pamela Z, Pluard, Timothy J, Toms, Steven A, Tse, Victor, Peak, Scott, Villano, John L, Battiste, James D, Mulholland, Paul J, Pearlman, Michael L, Petrecca, Kevin, Schulder, Michael, Prins, Robert M, Boynton, Alton L, and Bosch, Marnix L

Abstract

ImportanceGlioblastoma is the most lethal primary brain cancer. Clinical outcomes for glioblastoma remain poor, and new treatments are needed.ObjectiveTo investigate whether adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax-L) to standard of care (SOC) extends survival among patients with glioblastoma.Design, setting, and participantsThis phase 3, prospective, externally controlled nonrandomized trial compared overall survival (OS) in patients with newly diagnosed glioblastoma (nGBM) and recurrent glioblastoma (rGBM) treated with DCVax-L plus SOC vs contemporaneous matched external control patients treated with SOC. This international, multicenter trial was conducted at 94 sites in 4 countries from August 2007 to November 2015. Data analysis was conducted from October 2020 to September 2021.InterventionsThe active treatment was DCVax-L plus SOC temozolomide. The nGBM external control patients received SOC temozolomide and placebo; the rGBM external controls received approved rGBM therapies.Main outcomes and measuresThe primary and secondary end points compared overall survival (OS) in nGBM and rGBM, respectively, with contemporaneous matched external control populations from the control groups of other formal randomized clinical trials.ResultsA total of 331 patients were enrolled in the trial, with 232 randomized to the DCVax-L group and 99 to the placebo group. Median OS (mOS) for the 232 patients with nGBM receiving DCVax-L was 19.3 (95% CI, 17.5-21.3) months from randomization (22.4 months from surgery) vs 16.5 (95% CI, 16.0-17.5) months from randomization in control patients (HR = 0.80; 98% CI, 0.00-0.94; P = .002). Survival at 48 months from randomization was 15.7% vs 9.9%, and at 60 months, it was 13.0% vs 5.7%. For 64 patients with rGBM receiving DCVax-L, mOS was 13.2 (95% CI, 9.7-16.8) months from relapse vs 7.8 (95% CI, 7.2-8.2) months among control patients (HR, 0.58; 98% CI, 0.00-0.76; P < .001). Survival at 24 and 30 months after rec

Published
2023

53. Long-term survival with IDH wildtype glioblastoma:first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)

Author

Hertler, Caroline, Felsberg, Jörg, Gramatzki, Dorothee, Le Rhun, Emilie, Clarke, Jennifer, Soffietti, Riccardo, Wick, Wolfgang, Chinot, Olivier, Ducray, François, Roth, Patrick, McDonald, Kerrie, Hau, Peter, Hottinger, Andreas F., Reijneveld, Jaap, Schnell, Oliver, Marosi, Christine, Glantz, Michael, Darlix, Amélie, Lombardi, Giuseppe, Krex, Dietmar, Glas, Martin, Reardon, David A., van den Bent, Martin, Lefranc, Florence, Herrlinger, Ulrich, Razis, Evangelia, Carpentier, Antoine F., Phillips, Samuel, Rudà, Roberta, Wick, Antje, Tabouret, Emeline, Meyronet, David, Maurage, Claude Alain, Rushing, Elisabeth, Rapkins, Robert, Bumes, Elisabeth, Hegi, Monika, Weyerbrock, Astrid, Aregawi, Dawit, Gonzalez-Gomez, Christian, Pellerino, Alessia, Klein, Martin, Preusser, Matthias, Bendszus, Martin, Golfinopoulos, Vassilis, von Deimling, Andreas, Gorlia, Thierry, Wen, Patrick Y., Reifenberger, Guido, Weller, Michael, Hertler, Caroline, Felsberg, Jörg, Gramatzki, Dorothee, Le Rhun, Emilie, Clarke, Jennifer, Soffietti, Riccardo, Wick, Wolfgang, Chinot, Olivier, Ducray, François, Roth, Patrick, McDonald, Kerrie, Hau, Peter, Hottinger, Andreas F., Reijneveld, Jaap, Schnell, Oliver, Marosi, Christine, Glantz, Michael, Darlix, Amélie, Lombardi, Giuseppe, Krex, Dietmar, Glas, Martin, Reardon, David A., van den Bent, Martin, Lefranc, Florence, Herrlinger, Ulrich, Razis, Evangelia, Carpentier, Antoine F., Phillips, Samuel, Rudà, Roberta, Wick, Antje, Tabouret, Emeline, Meyronet, David, Maurage, Claude Alain, Rushing, Elisabeth, Rapkins, Robert, Bumes, Elisabeth, Hegi, Monika, Weyerbrock, Astrid, Aregawi, Dawit, Gonzalez-Gomez, Christian, Pellerino, Alessia, Klein, Martin, Preusser, Matthias, Bendszus, Martin, Golfinopoulos, Vassilis, von Deimling, Andreas, Gorlia, Thierry, Wen, Patrick Y., Reifenberger, Guido, and Weller, Michael

Abstract

Background: Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined. Methods: European Organization for Research and Treatment of Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by the Brain Tumor Funders Collaborative in the US and the EORTC Brain Tumor Group. Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model. A population-based reference cohort was obtained from the Cantonal cancer registry Zurich. Results: At the database lock of July 2020, 280 patients with histologically centrally confirmed glioblastoma (189 IDH wildtype, 80 IDH mutant, 11 incompletely characterised) had been registered. In the IDH wildtype population, median age was 56 years (range 24–78 years), 96 patients (50.8%) were female, 139 patients (74.3%) had tumours with O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Median overall survival was 9.9 years (95% confidence interval [95% CI] 7.9–11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) of MGMT promoter-unmethylated tumours. Conclusions: Freedom from progression is a powerful predictor of overall survival in long-term survivors with glioblastoma. Patients without relapse often have MGMT promoter-unmethylated glioblastoma and may represent a distinct subtype of glioblastoma.

Published
2023

54. Long-term neurocognitive function and quality of life after multimodal therapy in adult glioma patients: a prospective long-term follow-up

Author

Pertz, Milena; https://orcid.org/0000-0002-4275-2492, Schlömer, Sabine, Seidel, Clemens, Hentschel, Bettina, Löffler, Markus, Schackert, Gabriele, Krex, Dietmar, Juratli, Tareq, Tonn, Joerg Christian, Schnell, Oliver, Vatter, Hartmut, Simon, Matthias, Westphal, Manfred, Martens, Tobias, Sabel, Michael, Bendszus, Martin, Dörner, Nils, Wick, Antje, Fliessbach, Klaus, Hoppe, Christian, Klingner, Marcel, Felsberg, Jörg, Reifenberger, Guido, Gramatzki, Dorothee, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Schlegel, Uwe, German Glioma Network, Pertz, Milena; https://orcid.org/0000-0002-4275-2492, Schlömer, Sabine, Seidel, Clemens, Hentschel, Bettina, Löffler, Markus, Schackert, Gabriele, Krex, Dietmar, Juratli, Tareq, Tonn, Joerg Christian, Schnell, Oliver, Vatter, Hartmut, Simon, Matthias, Westphal, Manfred, Martens, Tobias, Sabel, Michael, Bendszus, Martin, Dörner, Nils, Wick, Antje, Fliessbach, Klaus, Hoppe, Christian, Klingner, Marcel, Felsberg, Jörg, Reifenberger, Guido, Gramatzki, Dorothee, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Schlegel, Uwe, and German Glioma Network

Abstract

PURPOSE: Multimodal therapies have significantly improved prognosis in glioma. However, in particular radiotherapy may induce long-term neurotoxicity compromising patients' neurocognition and quality of life. The present prospective multicenter study aimed to evaluate associations of multimodal treatment with neurocognition with a particular focus on hippocampal irradiation. METHODS: Seventy-one glioma patients (WHO grade 1-4) were serially evaluated with neurocognitive testing and quality of life questionnaires. Prior to (baseline) and following further treatment (median 7.1 years [range 4.6-11.0] after baseline) a standardized computerized neurocognitive test battery (NeuroCog FX) was applied to gauge psychomotor speed and inhibition, verbal short-term memory, working memory, verbal and non-verbal memory as well as verbal fluency. Mean ipsilateral hippocampal radiation dose was determined in a subgroup of 27 patients who received radiotherapy according to radiotherapy plans to evaluate its association with neurocognition. RESULTS: Between baseline and follow-up mean performance in none of the cognitive domains significantly declined in any treatment modality (radiotherapy, chemotherapy, combined radio-chemotherapy, watchful-waiting), except for selective attention in patients receiving chemotherapy alone. Apart from one subtest (inhibition), mean ipsilateral hippocampal radiation dose > 50 Gy (Dmean) as compared to < 10 Gy showed no associations with long-term cognitive functioning. However, patients with Dmean < 10 Gy showed stable or improved performance in all cognitive domains, while patients with > 50 Gy numerically deteriorated in 4/8 domains. CONCLUSIONS: Multimodal glioma therapy seems to affect neurocognition less than generally assumed. Even patients with unilateral hippocampal irradiation with > 50 Gy showed no profound cognitive decline in this series.

Published
2023

55. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)

Author

Hertler, Caroline; https://orcid.org/0000-0001-6181-2895, Felsberg, Jörg, Gramatzki, Dorothee; https://orcid.org/0000-0002-9054-5498, Le Rhun, Emilie; https://orcid.org/0000-0002-9408-3278, Clarke, Jennifer; https://orcid.org/0000-0002-8054-7342, Soffietti, Riccardo; https://orcid.org/0000-0002-9204-7038, Wick, Wolfgang, Chinot, Olivier, Ducray, François, Roth, Patrick, McDonald, Kerrie, Hau, Peter, Hottinger, Andreas F, Reijneveld, Jaap, Schnell, Oliver; https://orcid.org/0000-0002-1284-1427, Marosi, Christine, Glantz, Michael, Darlix, Amélie, Lombardi, Giuseppe, Krex, Dietmar, Glas, Martin, Reardon, David A, van den Bent, Martin; https://orcid.org/0000-0001-5710-5127, Lefranc, Florence, Herrlinger, Ulrich, Razis, Evangelia, Carpentier, Antoine F, Phillips, Samuel, Rudà, Roberta, Wick, Antje, et al, Rushing, Elisabeth; https://orcid.org/0000-0001-7616-6320, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Hertler, Caroline; https://orcid.org/0000-0001-6181-2895, Felsberg, Jörg, Gramatzki, Dorothee; https://orcid.org/0000-0002-9054-5498, Le Rhun, Emilie; https://orcid.org/0000-0002-9408-3278, Clarke, Jennifer; https://orcid.org/0000-0002-8054-7342, Soffietti, Riccardo; https://orcid.org/0000-0002-9204-7038, Wick, Wolfgang, Chinot, Olivier, Ducray, François, Roth, Patrick, McDonald, Kerrie, Hau, Peter, Hottinger, Andreas F, Reijneveld, Jaap, Schnell, Oliver; https://orcid.org/0000-0002-1284-1427, Marosi, Christine, Glantz, Michael, Darlix, Amélie, Lombardi, Giuseppe, Krex, Dietmar, Glas, Martin, Reardon, David A, van den Bent, Martin; https://orcid.org/0000-0001-5710-5127, Lefranc, Florence, Herrlinger, Ulrich, Razis, Evangelia, Carpentier, Antoine F, Phillips, Samuel, Rudà, Roberta, Wick, Antje, et al, Rushing, Elisabeth; https://orcid.org/0000-0001-7616-6320, and Weller, Michael; https://orcid.org/0000-0002-1748-174X

Abstract

Background: Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined. Methods: European Organization for Research and Treatment of Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by the Brain Tumor Funders Collaborative in the US and the EORTC Brain Tumor Group. Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model. A population-based reference cohort was obtained from the Cantonal cancer registry Zurich. Results: At the database lock of July 2020, 280 patients with histologically centrally confirmed glioblastoma (189 IDH wildtype, 80 IDH mutant, 11 incompletely characterised) had been registered. In the IDH wildtype population, median age was 56 years (range 24-78 years), 96 patients (50.8%) were female, 139 patients (74.3%) had tumours with O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Median overall survival was 9.9 years (95% confidence interval [95% CI] 7.9-11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) of MGMT promoter-unmethylated tumours. Conclusions: Freedom from progression is a powerful predictor of overall survival in long-term survivors with glioblastoma. Patients without relapse often have MGMT promoter-unmethylated glioblastoma and may represent a distinct subtype of glioblastoma.

Published
2023

57. NIMG-32. POSTPROGRESSION SURVIVAL AND MRI FEATURES AT PROGRESSION IN MGMT-METHYLATED GLIOBLASTOMA FOLLOWING TEMOZOLOMIDE (TMZ) OR CCNU/TMZ THERAPY - AN ANALYSIS OF THE CETEG/NOA-09-TRIAL

Author

Zeyen, Thomas, primary, Paech, Daniel, additional, Weller, Johannes, additional, Schäfer, Niklas, additional, Tzaridis, Theophilos, additional, Duffy, Cathrina, additional, Nitsch, Louisa, additional, Schneider, Matthias, additional, Steinbach, Joachim, additional, Hau, Peter, additional, Schlegel, Uwe, additional, Seidel, Clemens, additional, Krex, Dietmar, additional, Grauer, Oliver, additional, Goldbrunner, Roland, additional, Zeiner, Pia, additional, Tabatabai, Ghazaleh, additional, Galldiks, Norbert, additional, Stummer, Walter, additional, Hattingen, Elke, additional, Glas, Martin, additional, Radbruch, Alexander, additional, Herrlinger, Ulrich, additional, and Schaub, Christina, additional

Published
2022
Full Text
View/download PDF

58. CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL

Author

Liau, Linda M, primary, Ashkan, Keyoumars, additional, Brem, Steven, additional, Campian, Jian, additional, Trusheim, John, additional, Iwamoto, Fabio, additional, Tran, David, additional, Anstass, George, additional, Cobbs, Charles, additional, Heth, Jason, additional, Salacz, Michael, additional, D'Andre, Stacy, additional, Aiken, Robert, additional, Moshel, Yaron, additional, Nam, JooYeon, additional, Pillainayagam, Clement, additional, Wagner, Stephanie, additional, Walter, Kevin, additional, Chaudary, Rekha, additional, Goldlust, Samuel, additional, Lee, Ian, additional, Bota, Daniela, additional, Elinzano, Heinrich, additional, Grewal, Jai, additional, Lillehei, Kevin, additional, Mikkelsen, Tom, additional, Walbert, Tobias, additional, Abram, Steve, additional, Brenner, Andrew, additional, Ewend, Matthew, additional, Khagi, Simon, additional, Lovick, Darren, additional, Portnow, Jana, additional, Kim, Lyndon, additional, Loudon, William, additional, Martinez, Nina, additional, Thompson, Reid, additional, Avigan, David, additional, Fink, Karen, additional, Geoffroy, Francois, additional, Giglio, Pierre, additional, Gligich, Oleg, additional, Krex, Dietmar, additional, Lindhorst, Scott M, additional, Lutzky, Jose, additional, Meisel, Hans-Joerg, additional, Nadji-Ohl, Minou, additional, Sanchin, Lhagva, additional, Sloan, Andrew, additional, and Bosch, Marnix, additional

Published
2022
Full Text
View/download PDF

59. CTNI-29. INVESTIGATING SAFETY AND EFFICACY OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA - FIRST RESULTS OF THE PRICOTTF PHASE I/II TRIAL

Author

Kebir, Sied, primary, Lazaridis, Lazaros, additional, Schmidt, Teresa, additional, Oster, Christoph, additional, Feldheim, Jonas, additional, Pierscianek, Daniela, additional, Proescholdt, Martin, additional, Hau, Peter, additional, Grosu, Anca-Ligia, additional, Krex, Dietmar, additional, Sure, Ulrich, additional, Scheffler, Björn, additional, Kleinschnitz, Christoph, additional, Pöttgen, Christoph, additional, Stuschke, Martin, additional, and Glas, Martin, additional

Published
2022
Full Text
View/download PDF

63. Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma

Author

Scholz, Alexander, Harter, Patrick N, Cremer, Sebastian, Yalcin, Burak H, Gurnik, Stefanie, Yamaji, Maiko, Di Tacchio, Mariangela, Sommer, Kathleen, Baumgarten, Peter, Bähr, Oliver, Steinbach, Joachim P, Trojan, Jörg, Glas, Martin, Herrlinger, Ulrich, Krex, Dietmar, Meinhardt, Matthias, Weyerbrock, Astrid, Timmer, Marco, Goldbrunner, Roland, Deckert, Martina, Braun, Christian, Schittenhelm, Jens, Frueh, Jochen T, Ullrich, Evelyn, Mittelbronn, Michel, Plate, Karl H, and Reiss, Yvonne

Published
2016
Full Text
View/download PDF

64. Genomische Charakterisierung der IDH-Wildtyp Glioblastome in verschiedenen Altersgruppen

Author

Richter, Sven, Stasik, Sebastian, Schackert, Gabriele, Thiede, Christian, Krex, Dietmar, and Juratli, Tareq

Subjects
ddc: 610, Medicine and health, nervous system diseases
Abstract

Objective:IDH-wildtype Glioblastomas (IDH-wt GBM) are molecularly heterogeneous tumors with poor prognosis and a high incidence in the elderly population. However, IDH-wt GBM may occur in young patients and are associated with a relatively better prognosis. Here, we sought to explore whether IDH-wt [for full text, please go to the a.m. URL]

Published
2022

65. Der Stellenwert der Chirurgie bei Patienten mit Melanom-Hirnmetastasen nach Einführung der Checkpoint- und BRAF/MEK Inhibitor Therapie

Author

Harlaß, Sophia, Hennig, Silke, Schackert, Gabriele, Meier, Friedegund, and Krex, Dietmar

Subjects
ddc: 610, Medicine and health
Abstract

Objective: The implementation of checkpoint-inhibitor immunotherapy (CII) and inhibition of BRAF/MEK signaling pathway (BMI) in the treatment of malignant melanoma (MM) has dramatically improved survival-data of those patients. In consequence, the number of patients with MM brain metastasis (MMBM), [for full text, please go to the a.m. URL]

Published
2022

66. Prädiktion des IDH-Mutationsstatus in Gliomen mittels 2-Hydroxyglutarat Magnetresonanzspektorskopie

Author

Juratli, Tareq, Daubner, Dirk, Peitzsch, Mirko, Eisenhofer, Graeme, Schackert, Gabriele, Krex, Dietmar, Linn, Jennifer, and Werner, Annett

Subjects
ddc: 610, Medicine and health, neoplasms
Abstract

Objective: Non-invasive and accurate diagnostic techniques to detect isocitrate dehydrogenase (IDH) mutant glioma have great potential in routine clinical practice. To date, only a few centers worldwide were able to establish 2HG detection by magnetic resonance spectroscopy (MRS) in glioma. Here, we [for full text, please go to the a.m. URL]

Published
2022
Full Text
View/download PDF

68. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

Author

Weller, Michael, Weber, Ruthild G., Willscher, Edith, Riehmer, Vera, Hentschel, Bettina, Kreuz, Markus, Felsberg, Jörg, Beyer, Ulrike, Löffler-Wirth, Henry, Kaulich, Kerstin, Steinbach, Joachim P., Hartmann, Christian, Gramatzki, Dorothee, Schramm, Johannes, Westphal, Manfred, Schackert, Gabriele, Simon, Matthias, Martens, Tobias, Boström, Jan, Hagel, Christian, Sabel, Michael, Krex, Dietmar, Tonn, Jörg C., Wick, Wolfgang, Noell, Susan, Schlegel, Uwe, Radlwimmer, Bernhard, Pietsch, Torsten, Loeffler, Markus, von Deimling, Andreas, Binder, Hans, and Reifenberger, Guido

Published
2015
Full Text
View/download PDF

69. Common variant near the endothelin receptor type A (EDNRA) gene is associated with intracranial aneurysm risk

Author

Yasuno, Katsuhito, Bakırcıoğlu, Mehmet, Low, Siew-Kee, Bilgüvar, Kaya, Gaál, Emília, Ruigrok, Ynte M., Niemelä, Mika, Hata, Akira, Bijlenga, Philippe, Kasuya, Hidetoshi, Jääskeläinen, Juha E., Krex, Dietmar, Auburger, Georg, Simon, Matthias, Krischek, Boris, Ozturk, Ali K., Mane, Shrikant, Rinkel, Gabriel J. E., Steinmetz, Helmuth, Hernesniemi, Juha, Schaller, Karl, Zembutsu, Hitoshi, Inoue, Ituro, Palotie, Aarno, Cambien, François, Nakamura, Yusuke, Lifton, Richard P., and Günel, Murat

Published
2011

75. BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA

Author

Weller, Johannes, primary, Waha, Andreas, additional, Schneider, Matthias, additional, Seidel, Clemens, additional, Steinbach, Joachim, additional, Hau, Peter, additional, Schlegel, Uwe, additional, Tonn, Jörg-Christian, additional, Grauer, Oliver, additional, Sabel, Michael, additional, Krex, Dietmar, additional, Schnell, Oliver, additional, Ringel, Florian, additional, Tabatabai, Ghazaleh, additional, Goldbrunner, Roland, additional, Radbruch, Alexander, additional, Schuss, Patrick, additional, Güresir, Erdem, additional, Vatter, Hartmut, additional, Glas, Martin, additional, Schmid, Matthias, additional, Schäfer, Niklas, additional, Tzaridis, Theophilos, additional, Giordano, Frank, additional, Zeyen, Thomas, additional, Schaub, Christina, additional, Németh, Robert, additional, Pietsch, Torsten, additional, and Herrlinger, Ulrich, additional

Published
2021
Full Text
View/download PDF

77. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

Author

Weller, Michael, Weber, Ruthild, Willscher, Edith, Riehmer, Vera, Hentschel, Bettina, Kreuz, Markus, Felsberg, Jörg, Beyer, Ulrike, Löffler-Wirth, Henry, Kaulich, Kerstin, Steinbach, Joachim, Hartmann, Christian, Gramatzki, Dorothee, Schramm, Johannes, Westphal, Manfred, Schackert, Gabriele, Simon, Matthias, Martens, Tobias, Boström, Jan, Hagel, Christian, Sabel, Michael, Krex, Dietmar, Tonn, Jörg, Wick, Wolfgang, Noell, Susan, Schlegel, Uwe, Radlwimmer, Bernhard, Pietsch, Torsten, Loeffler, Markus, von Deimling, Andreas, Binder, Hans, Reifenberger, Guido, Weller, Michael, Weber, Ruthild, Willscher, Edith, Riehmer, Vera, Hentschel, Bettina, Kreuz, Markus, Felsberg, Jörg, Beyer, Ulrike, Löffler-Wirth, Henry, Kaulich, Kerstin, Steinbach, Joachim, Hartmann, Christian, Gramatzki, Dorothee, Schramm, Johannes, Westphal, Manfred, Schackert, Gabriele, Simon, Matthias, Martens, Tobias, Boström, Jan, Hagel, Christian, Sabel, Michael, Krex, Dietmar, Tonn, Jörg, Wick, Wolfgang, Noell, Susan, Schlegel, Uwe, Radlwimmer, Bernhard, Pietsch, Torsten, Loeffler, Markus, von Deimling, Andreas, Binder, Hans, and Reifenberger, Guido

Abstract

Cerebral gliomas of World Health Organization (WHO) grade II and III represent a major challenge in terms of histological classification and clinical management. Here, we asked whether large-scale genomic and transcriptomic profiling improves the definition of prognostically distinct entities. We performed microarray-based genome- and transcriptome-wide analyses of primary tumor samples from a prospective German Glioma Network cohort of 137 patients with cerebral gliomas, including 61 WHO grade II and 76 WHO grade III tumors. Integrative bioinformatic analyses were employed to define molecular subgroups, which were then related to histology, molecular biomarkers, including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation, 1p/19q co-deletion and telomerase reverse transcriptase (TERT) promoter mutations, and patient outcome. Genomic profiling identified five distinct glioma groups, including three IDH1/2 mutant and two IDH1/2 wild-type groups. Expression profiling revealed evidence for eight transcriptionally different groups (five IDH1/2 mutant, three IDH1/2 wild type), which were only partially linked to the genomic groups. Correlation of DNA-based molecular stratification with clinical outcome allowed to define three major prognostic groups with characteristic genomic aberrations. The best prognosis was found in patients with IDH1/2 mutant and 1p/19q co-deleted tumors. Patients with IDH1/2 wild-type gliomas and glioblastoma-like genomic alterations, including gain on chromosome arm 7q (+7q), loss on chromosome arm 10q (−10q), TERT promoter mutation and oncogene amplification, displayed the worst outcome. Intermediate survival was seen in patients with IDH1/2 mutant, but 1p/19q intact, mostly astrocytic gliomas, and in patients with IDH1/2 wild-type gliomas lacking the +7q/−10q genotype and TERT promoter mutation. This molecular subgrouping stratified patients into prognostically distinct groups better than histological classification. Addition of gene expression

Published
2021

78. Telomerase reverse transcriptase promoter mutation- and O 6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?

Author

Gramatzki, Dorothee, Felsberg, Jörg, Hentschel, Bettina, Wolter, Marietta, Schackert, Gabriele, Westphal, Manfred, Regli, Luca, Thon, Niklas, Tatagiba, Marcos, Wick, Wolfgang, Schlegel, Uwe, Krex, Dietmar, Matschke, Jakob, Roth, Patrick, Suresh, Marian P, Kamp, Marcel A, Rushing, Elisabeth J, Pietsch, Torsten, von Deimling, Andreas, Sabel, Michael, Loeffler, Markus, Weller, Michael, Reifenberger, Guido, Gramatzki, Dorothee, Felsberg, Jörg, Hentschel, Bettina, Wolter, Marietta, Schackert, Gabriele, Westphal, Manfred, Regli, Luca, Thon, Niklas, Tatagiba, Marcos, Wick, Wolfgang, Schlegel, Uwe, Krex, Dietmar, Matschke, Jakob, Roth, Patrick, Suresh, Marian P, Kamp, Marcel A, Rushing, Elisabeth J, Pietsch, Torsten, von Deimling, Andreas, Sabel, Michael, Loeffler, Markus, Weller, Michael, and Reifenberger, Guido

Abstract

AIM OF THE STUDY: Benefit from temozolomide (TMZ) chemotherapy in the treatment of isocitrate dehydrogenase (IDH)-wild-type glioblastoma is essentially limited to patients with O$^{6}$-methylguanine DNA methyltransferase (MGMT) promoter-methylated tumours. Recent studies suggested that telomerase reverse transcriptase (TERT) promoter hotspot mutations may have an impact on the prognostic role of the MGMT status in patients with glioblastoma. METHODS: MGMT promoter methylation and TERT promoter mutation status were retrospectively assessed in a prospective cohort of patients with IDH-wild-type glioblastoma of the German Glioma Network (GGN) (n = 298) and an independent retrospective cohort from Düsseldorf, Germany, and Zurich, Switzerland (n = 302). RESULTS: In the GGN cohort, but not in the Düsseldorf/Zurich cohort, TERT promoter mutation was moderately associated with inferior outcomes in patients with MGMT promoter-unmethylated tumours (hazard ratio 1.74; 95% confidence interval: 1.07-2.82; p = 0.026). TERT promoter mutations were not associated with better outcomes in patients with MGMT promoter-methylated tumours in either cohort. The two different TERT promoter hotspot mutations (C228T and C250T) were not linked to distinct outcomes. CONCLUSIONS: Analysis of two independent cohorts of patients with glioblastoma did not confirm previous data, suggesting that TERT promoter mutations confer an enhanced benefit from TMZ in patients with MGMT promoter-methylated glioblastoma. Thus, diagnostic testing for TERT promoter mutations may not be required for prediction of TMZ sensitivity in patients with IDH-wild-type glioblastoma.

Published
2021

83. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

Author

Dresemann, Gregor, Weller, Michael, Rosenthal, Mark A., Wedding, Ulrich, Wagner, Wolfgang, Engel, Erik, Heinrich, Bernhard, Mayer-Steinacker, Regine, Karup-Hansen, Anders, Fluge, Øystein, Nowak, Anna, Mehdorn, Maximilian, Schleyer, Eberhard, Krex, Dietmar, Olver, Ian N., Steinbach, Joachim P., Hosius, Christian, Sieder, Christian, Sorenson, Greg, Parker, Richard, and Nikolova, Zariana

Published
2010
Full Text
View/download PDF

84. Telomerase reverse transcriptase promoter mutation– and O6-methylguanine DNA methyltransferase promoter methylation–mediated sensitivity to temozolomide in isocitrate dehydrogenase–wild-type glioblastoma: is there a link?

Author

Gramatzki, Dorothee, primary, Felsberg, Jörg, additional, Hentschel, Bettina, additional, Wolter, Marietta, additional, Schackert, Gabriele, additional, Westphal, Manfred, additional, Regli, Luca, additional, Thon, Niklas, additional, Tatagiba, Marcos, additional, Wick, Wolfgang, additional, Schlegel, Uwe, additional, Krex, Dietmar, additional, Matschke, Jakob, additional, Roth, Patrick, additional, Suresh, Marian P., additional, Kamp, Marcel A., additional, Rushing, Elisabeth J., additional, Pietsch, Torsten, additional, von Deimling, Andreas, additional, Sabel, Michael, additional, Loeffler, Markus, additional, Weller, Michael, additional, and Reifenberger, Guido, additional

Published
2021
Full Text
View/download PDF

85. Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma

Author

Seidlitz, Annekatrin, primary, Beuthien-Baumann, Bettina, additional, Löck, Steffen, additional, Jentsch, Christina, additional, Platzek, Ivan, additional, Zöphel, Klaus, additional, Linge, Annett, additional, Kotzerke, Jörg, additional, Petr, Jan, additional, van den Hoff, Jörg, additional, Steinbach, Jörg, additional, Krex, Dietmar, additional, Schmitz-Schackert, Gabriele, additional, Falk, Monique, additional, Baumann, Michael, additional, and Krause, Mechthild, additional

Published
2021
Full Text
View/download PDF

87. Aurora B-Kinase-Inhibitor und Therapie mit elektrischen Feldern als neues adjuvantes Therapiekonzept in der Behandlung maligner Glioblastomrezidive

Author

Krex, Dietmar, Schaich, Markus, Technische Universität Dresden, Lachmann, Doris, Krex, Dietmar, Schaich, Markus, Technische Universität Dresden, and Lachmann, Doris

Abstract

Mit einem medianen Überleben von 14 bis 16 Monaten und einer 5-Jahres-Überlebensrate von weniger als 5 % zählt das Glioblastoma multiforme (GBM) zu den aggressivsten Tumoren des zentralen Nervensystems (Cloughesy et al., 2014; Batash et al., 2017; Guberina et al., 2020). Das GBM, auch als WHO-Grad IV-Astrozytom bezeichnet, ist mit > 50 % aller glialen Tumoren der häufigste maligne hirneigene Tumor (Ohgaki und Kleihues, 2005). Aufgrund ihrer infausten Prognose ist eine Weiterentwicklung und Optimierung der aktuellen Leitlinientherapie sowie die Entwicklung neuartiger Therapiekonzepte für Primärtumore und Rezidive unentbehrlich. Im Rahmen dieser Arbeit wurden neuartige Therapieansätze, wie elektrische Wechselfelder (tumor treating fields, TTFields) und der Aurorakinaseinhibitor AZD1152 sowie die konventionelle, in der Leitlinie des Primärtumors verankerte Radiotherapie eingesetzt. Während eine Strahlentherapie in erster Linie durch die Induktion von DNA-Einzel- und Doppelstrangbrüchen wirkt, beruht der Wirkmechanismus der TTFields auf eine Störung der Dipol-gesteuerten Schritte während der Zellteilung. Dies führt folglich zu einer Arretierung des Zellzyklus in der G2/M- und G1/S-Phase. Sofern eine Reparatur an den checkpoints nicht möglich ist, erfolgt die Überleitung der Zelle in die Apoptose (Suzuki et al., 2003; Wilson et al., 2014; Fontana et al., 2015; Gerelchuluun et al., 2015). Die TTFields kamen mittels des InovitroTM-Systems zum Einsatz, die insbesondere inhibierend auf die M-Phase des Zellzyklus wirken (Gutin und Wong, 2012; Saria und Kesari, 2016). Für das Glioblastoma multiforme wurde dabei eine spezifische Frequenz von 200 kHz und eine Feldintensität von 1,7 V/cm bestimmt, welche das außerhalb des Zielgebiets liegende Gewebe schont (Kirson et al., 2009; Fabian et al., 2019). Für Primärtumore eines Glioblastoma multiforme konnte in der EF-14-Studie bereits ein signifikant verlängertes Überleben durch TTFields bestätigt werden, während für das Rezidiv in de, With a median survival of 14 to 16 months and a 5-year survival rate of less than 5 %, glioblastoma multiforme (GBM) is one of the most aggressive tumours of the central nervous system (Cloughesy et al., 2014; Batash et al., 2017; Guberina et al., 2020). GBM, also known as WHO grade IV astrocytoma, is the most common malignant brain tumor with > 50% of all glial tumors (Ohgaki und Kleihues, 2005). Due to its dismal prognosis, further development and optimisation of the current guideline therapy as well as the development of novel therapeutic concepts for primary tumours and recurrences is indispensable. Within the framework of this work, novel therapeutic approaches such as alternating electric fields (tumor treating fields, TTFields) and the aurorakinase inhibitor AZD1152 as well as conventional radiotherapy anchored in the guideline of the primary tumor were applied. While radiotherapy primarily works by the induction of DNA single and double strand breaks, the mechanism of action of TTFields is based on a disruption of the dipole-controlled steps during cell division. Consequently, this leads to a locking of the cell cycle in the G2/M and G1/S phase. If repair at the checkpoints is not possible, the cell is transferred to apoptosis (Suzuki et al., 2003; Wilson et al., 2014; Fontana et al., 2015; Gerelchuluun et al., 2015). The TTFields were used by means of the InovitroTM system, which has a particularly inhibitory effect on the M-phase of the cell cycle (Gutin und Wong, 2012; Saria und Kesari, 2016). For glioblastoma multiforme, a specific frequency of 200 kHz and a field intensity of 1.7 V/cm was determined, which spares the tissue outside the target area (Kirson et al., 2009; Fabian et al., 2019). For primary tumours of glioblastoma multiforme a significantly prolonged survival could already be confirmed by TTFields in the EF 14 study, whereas for recurrent tumours only an improvement in quality of life was achieved in the EF 11 study (Stupp et al., 2012; Stup

Published
2020

90. Contributors

Author

Acosta, Frank L., primary, Adelson, P. David, additional, Adler, ., John R., additional, Aghayev, Kamran V., additional, Aghi, Manish K., additional, Agrawal, Basheal M., additional, Ahluwalia, Manmeet S., additional, Ahmad, Faiz, additional, Air, Ellen, additional, Ajler, Pablo, additional, Albuquerque, Felipe C., additional, Amar, Arun P., additional, Amendola, Luca, additional, Ames, Christopher, additional, Amin, Beejal Y., additional, Amin-Hanjani, Sepideh, additional, Ammerman, Joshua M., additional, Anderson, William S., additional, Apfelbaum, Ronald I., additional, Apuzzo, Michael L.J., additional, Armonda, Rocco, additional, Arnold, Paul M., additional, Arzi, Harel, additional, Asthagiri, Ashok R., additional, Auguste, Kurtis, additional, Awad, Tariq E., additional, Aziz, Khaled M., additional, Aziz, Tipu, additional, Baehring, Joachim M., additional, Baig, Mirza N., additional, Bakay, Roy, additional, Ball, Perry A., additional, Bandiera, Stefano, additional, Barbaro, Nicholas M., additional, Barker, Frederick G., additional, Barrow, Daniel L., additional, Batra, Sachin, additional, Bederson, Joshua, additional, Bekelis, Kimon, additional, Bellabarba, Carlo, additional, Bello, Lorenzo, additional, Belzberg, Allan J., additional, Bendok, Bernard R., additional, Benes, Ludwig, additional, Benzel, Edward C., additional, Bertalanffy, Helmut, additional, Bettegowda, Chetan, additional, Bhatia, Ravi, additional, Bhatia, Sanjay, additional, Bishop, Allen T., additional, Black, Keith L., additional, Blevins, Lewis S., additional, Blike, George T., additional, Blitz, Ari, additional, Blomstedt, Göran C., additional, Blondel, Benjamin, additional, Boahene, Kofi, additional, Boleaga, Bernardo, additional, Bookland, Markus, additional, Boriani, Stefano, additional, Boxell, Christopher M., additional, Brem, Henry, additional, Bricolo, Albino, additional, Brodkey, Jason A., additional, Brotchi, Jacques, additional, Bruce, Jeffrey N., additional, Bruneau, Michael, additional, Buchbinder, Bradley R., additional, Burchiel, Kim J., additional, Burke, Timothy G., additional, Bydon, Ali, additional, Cacciola, Francesco, additional, Cahill, Kevin, additional, Cappabianca, Paolo, additional, Caputy, Anthony J., additional, Cardinale, Francesco, additional, Carrau, Ricardo L., additional, Carson, Benjamin S., additional, Carter, Bob S., additional, Casaceli, Giuseppe, additional, Castana, Laura, additional, Castillo, Gabriel, additional, Cavallo, Luigi M., additional, Cawley, C. Michael, additional, Chakraborty, Aabir, additional, Chang, Edward F., additional, Chang, Eric C., additional, Chang, Steven D., additional, Chapman, Jens R., additional, Chappell, E. Thomas, additional, Chaudhary, Neeraj, additional, Chen, Douglas, additional, Chen, James, additional, Chen, Linda C., additional, Cheng, Boyle C., additional, Chern, Joshua J., additional, Chi, John H., additional, Chien, Wade W., additional, Chiocca, E. Antonio, additional, Chitale, Rohan, additional, Chitnavis, Bhupal, additional, Christiano, Lana D., additional, Chu, Ray M., additional, Ciceri, Elisa F., additional, Clarke, Michelle J., additional, Cohen, Alan, additional, Colao, Annamaria, additional, Colby, Geoffrey P., additional, Collice, Massimo, additional, Condit, Daniel, additional, Coon, Alexander L., additional, Corrêa Dos Reis, Cassius Vinícius, additional, Cosgrove, G. Rees, additional, Cossu, Massimo, additional, Couldwell, William T., additional, Curry, William T., additional, Dabus, Guilherme, additional, Dagi, Teodoro Forcht, additional, D'Aliberti, Giuseppe, additional, Danielpour, Moise, additional, Dannenbaum, Mark J., additional, Dardis, Ronan M., additional, Dasenbrock, Hormuzdiyar H., additional, Dashti, Reza, additional, Day, Arthur L., additional, Day, John Diaz, additional, Deletis, Vedran, additional, Del-Valle, Ramiro, additional, DeMonte, Franco, additional, Dimeco, Francesco, additional, Dodd, Robert, additional, Doglietto, Francesco, additional, Dörner, Lutz, additional, Dorsi, Michael J., additional, Doumit, Gaby D., additional, Drake, James M., additional, Drazin, Doniel, additional, Du, Rose, additional, Ducker, Thomas B., additional, Duffau, Hugues, additional, Duhon, Bradley S., additional, Eboli, Paula, additional, Elhammady, Mohamed Samy, additional, Ely, Pamela, additional, Epstein, Nancy E., additional, Erkmen, Kadir, additional, Errico, Thomas, additional, Eskandar, Emad N., additional, Eskey, Clifford J., additional, Esposito, Felice, additional, Fadul, Camilo E., additional, Fanciullo, Gilbert J., additional, Fargen, Kyle M., additional, Felsen, Gidon, additional, Feng, Dong Xia, additional, Fessler, Richard G., additional, Filler, Aaron G., additional, Flickinger, John C., additional, Floyd, John R., additional, Foley, Kevin T., additional, Fountas, Kostas N., additional, Francis, Howard, additional, Frazier, James L., additional, Frerichs, Kai, additional, Frim, David M., additional, Froelich, Sebastien, additional, Fukushima, Takanori, additional, Gailloud, Philippe, additional, Gaini, Sergio Maria, additional, Gandhi, Chirag D., additional, Gandhi, Dheeraj, additional, Gardner, Gale, additional, Gardner, Paul, additional, Garrett, Mark, additional, Garzón-Muvdi, Tomás, additional, Gasbarrini, Alessandro, additional, Geisler, Fred H., additional, Gemmete, Joseph J., additional, Gerosa, Massimo, additional, Goel, Atul, additional, Gokaslan, Ziya L., additional, Gonzalez, L. Fernando, additional, Goodwin, C. Rory, additional, Goto, Takeo, additional, Gould, Grahame C., additional, Grady, M. Sean, additional, Grande, Andrew W., additional, Grandhi, Ramesh, additional, Green, Alexander L., additional, Greenfield, Jeffrey P., additional, Gross, Bradley A., additional, Grossman, Rachel, additional, Groves, Mari, additional, Guinto, Gerardo, additional, Gullan, Richard, additional, Gupta, Gaurav, additional, Gupta, Nalin, additional, Hankinson, Todd C., additional, Hansasuta, Ake, additional, Harrop, James S., additional, Harsh, Griffith R., additional, Hdeib, Alia, additional, Heinze, Stefan, additional, Heiss, John, additional, Hellwig, Dieter, additional, Hernesniemi, Juha, additional, Heros, Roberto C., additional, Hillman, Todd, additional, Hinojosa, Jose, additional, Hiremath, Girish K., additional, Hoh, Brian L., additional, Hopkins, L. Nelson, additional, Hsu, Wesley, additional, Hu, Yin C., additional, Huang, Jason H., additional, Huang, Judy, additional, Hutchinson, Peter J., additional, Hyam, Jonathan A., additional, Ioachimescu, Adriana G., additional, Jabbour, Pascal M., additional, Jackson, Juan, additional, Jallo, George I., additional, Janecka, Ivo P., additional, Javadpour, Mohsen, additional, Jea, Andrew, additional, Jeswani, Sunil, additional, Jho, David H., additional, Jho, Diana H., additional, Jho, Hae-Dong, additional, Jiang, Bowen, additional, Jung, Tae-Young, additional, Kalani, M. Yashar S., additional, Kano, Hideyuki, additional, Kapadia, Silloo B., additional, Kaplitt, Michael G., additional, Kappus, Christoph, additional, Kapsalaki, Eftychia Z., additional, Karmon, Yuval, additional, Kassam, Amin B., additional, Kathuria, Sudhir, additional, Kawase, Takeshi, additional, Khalessi, Alexander A., additional, Khu, Kathleen, additional, Kim, Daniel H., additional, Kirsch ., Matthias, additional, Kivisaari, Riku, additional, Kolias, Angelos G., additional, Kondziolka, Douglas, additional, Korinth, Marcus C, additional, Krex, Dietmar, additional, Krieger, Mark D., additional, Krishnan, Kartik G., additional, Krishnaney, Ajit A., additional, Lacy, Maureen, additional, Lad, Santosh D., additional, Landeiro, Jose Alberto, additional, Lang, Frederick F., additional, Lang, Shih-Shan, additional, LaPierre, Françoise, additional, Larson, Paul S., additional, Lawton, Michael T., additional, Lee, Marco, additional, Lehecka, Martin, additional, Levi, Allan, additional, Levy, Elad I., additional, Lieberson, Robert E., additional, Lim, Michael, additional, Lin, Ning, additional, Lind, Göran, additional, Linderoth, Bengt, additional, Lindley, Timothy, additional, Listrat, Antoine, additional, Liu, Charles Y., additional, Liu, James K., additional, Liu, John C., additional, Lo Russo, Giorgio, additional, Loftus, Christopher M., additional, Lonser, Russell R., additional, Lu, Daniel C., additional, Lu, Yi, additional, Lunsford, L. Dade, additional, Macenski, M. Mason, additional, Maciaczyk, Jaroslaw, additional, Madsen, Joseph R., additional, Magge, Subu N., additional, Maira, Giulio, additional, Malessy, Martijn J.A., additional, Malone, David G., additional, Maniker, Allen, additional, Manley, Geoffrey T., additional, Manwaring, Jotham, additional, Martineau, Mitchell, additional, Martuza, Robert L., additional, Mathews, Marlon S., additional, Mathioudakis, Nestoras, additional, McCormick, Paul, additional, McDermott, Michael W., additional, McDougall, Cameron G., additional, Mehdorn, H. Maximilian, additional, Mehta, Vivek A., additional, Menezes, Arnold, additional, Mertens, Patrick, additional, Meyer, Frederic B., additional, Mian, Matthew K., additional, Midha, Rajiv, additional, San Millán Ruíz, Diego, additional, Miller, Jonathan, additional, Miller, Neil R., additional, Mirzadeh, Zaman, additional, Mishra, Ganpati Prasad, additional, Missios, Symeon, additional, Mitchell, James B., additional, Mitha, Alim, additional, Mocco, J., additional, Moghekar, Abhay, additional, Morcos, Jacques J., additional, Morgan, Chad J., additional, Morrison, John F., additional, Moyle, Henry, additional, Muh, Carrie R., additional, Mukherjee, Debraj, additional, Nabavi, Arya, additional, Nanaszko, Michael J., additional, Nandi, Dipankar, additional, Narayan, Raj, additional, Natarajan, Sabareesh K., additional, Nathal, Edgar, additional, Nayar, Vikram V., additional, Netalkar, Audumbar Shantaram, additional, Newman, C. Benjamin, additional, Nguyen, Trang, additional, Ngwenya, Laura B., additional, Nicolato, Antonio, additional, Niemelä, Mika, additional, Nikkhah, Guido, additional, Nimmagadda, Anitha, additional, Niparko, John K., additional, Niranjan, Ajay, additional, North, Richard B., additional, Núñez, José María, additional, Oakes, W. Jerry, additional, Ogilvy, Christopher S., additional, Ohata, Kenji, additional, Ojemann, Jeffrey G., additional, Ojemann, Steven, additional, Okonkwo, David O., additional, Oldfield, Edward H., additional, O'Neill, Brent, additional, Oyesiku, Nelson M., additional, Pallini, Roberto, additional, Pandey, Aditya S., additional, Pang, Dachling, additional, Papadimitriou, Kyriakos, additional, Pascual, José María, additional, Patel, Aman, additional, Patel, Anoop P., additional, Patel, Toral R., additional, Paterno, Vincenzo, additional, Patir, Rana, additional, Paul, Alexandra R., additional, Pawar, Sanjay J., additional, Penn, Richard, additional, Pereira, Erlick A.C., additional, Perez-Cruet, Mick J., additional, Peterson, Eric C., additional, Pichelmann, Mark A., additional, Piepmeier, Joseph M., additional, Pinsker, Marcus O., additional, Pitts, Lawrence H., additional, Placide, Rick J., additional, Pondaag, Willem, additional, Post, Kalmon, additional, Potts, Matthew B., additional, Poulsgaard, Lars, additional, Pradilla, Gustavo, additional, Prestigiacomo, Charles J., additional, Prevedello, Daniel M., additional, Prieto, Ruth, additional, Quiñones-Hinojosa, Alfredo, additional, Quintana, Leonidas M., additional, Rahimi, Scott Y., additional, Rahme, Rudy J., additional, Ramos-Zúñiga, Rodrigo, additional, Ranalli, Nathan J., additional, Raza, Shaan M., additional, Recinos, Pablo F., additional, Recinos, Violette Renard, additional, Rege, Shrikant, additional, Reithmeier, Thomas, additional, Relyea, Katherine, additional, Resnick, Daniel, additional, Rigamonti, Daniele, additional, Rigoard, Philippe, additional, Rinne, Jaakko, additional, Robertson, Jon H., additional, Rochkind, Shimon, additional, Rock, Jack P., additional, Romani, Rossana, additional, Rosenthal, Guy, additional, Rosenwasser, Robert H., additional, Rowland, Nathan C., additional, Rutka, James T., additional, Ryu, Samuel, additional, Sala, Francesco, additional, Salvatori, Roberto, additional, Sammalkorpi, Kari, additional, Sanai, Nader, additional, Santarius, Thomas, additional, Saxena, Amar, additional, Schackert, Gabriele, additional, Schick, Uta, additional, Schildhauer, Thomas A., additional, Schmidek, Alexandra, additional, Schmidek, Henry H., additional, Schmidt, Meic H., additional, Schmitt, Paul, additional, Schramm, Johannes, additional, Schwab, Joseph, additional, Schwartz, Theodore H., additional, Schweder, Patrick, additional, Sciubba, Daniel M., additional, Scott, R. Michael, additional, Sekula, Raymond F., additional, Senatus, Patrick, additional, Shad, Amjad, additional, Shaibani, Ali, additional, Sharma, Manish S., additional, Sharma, Rewati Raman, additional, Sheth, Sameer A., additional, Shin, Alexander Y., additional, Shirzadi, Ali, additional, Siddiqui, Adnan H., additional, Silveira, Roberto Leal, additional, Simmons, Nathan E., additional, Sindou, Marc, additional, Sinisi, Marco, additional, Siu, Timothy, additional, Smith, Edward, additional, Smith, Joseph R., additional, Smith, Patricia, additional, Smyth, Matthew, additional, Solari, Domenico, additional, Solomon, David, additional, Sonabend, Adam M., additional, Souweidane, Mark M., additional, Spagnuolo, Edgardo, additional, Spetzler, Robert F., additional, Spinner, Robert J., additional, Stark, Andreas M., additional, Starr, Philip A., additional, Steiner, Ladislau, additional, Steinmetz, Michael P., additional, Stiver, Shirley I., additional, Subramanian, Prem, additional, Sughrue, Michael E., additional, Suk, Ian, additional, Sun, Daniel Q., additional, Sure, Ulrich, additional, Szentirmai, Oszkar, additional, Taghva, Alexander, additional, Talamonti, Giuseppe, additional, Tamargo, Rafael J., additional, Teff, Richard J., additional, Tew, John M., additional, Theodore, Nicholas, additional, Theodosopoulos, Philip V., additional, Thompson, B. Gregory, additional, Tirakotai, Wuttipong, additional, Tjoumakaris, Stavropoula I., additional, Tonsgard, James H., additional, Trejo, David, additional, Trippel, Michael, additional, Tubbs, R. Shane, additional, Tumialan, Luis M., additional, Unterberg, Andreas, additional, Vaphiades, Michael S., additional, Vaughan, T. Brooks, additional, Veeravagu, Anand, additional, Velasco, Ana Luisa, additional, Velasco, Francisco, additional, Velat, Gregory J., additional, Verlicchi, Angela, additional, Vrionis, Frank D., additional, Wager, Michel, additional, Wallace, M. Christopher, additional, Wand, Gary S., additional, Warf, Benjamin C., additional, Waters, Michael F., additional, Watson, Joseph, additional, Weiss, Martin H., additional, Weiss, Nirit, additional, Welch, William, additional, Werner, J. Kent, additional, Whitworth, Louis A., additional, Winfree, Christopher, additional, Witham, Timothy F., additional, Wolinsky, Jean-Paul, additional, Wong, Judith M., additional, Xavier, Shaun, additional, Yamini, Bakhtiar, additional, Yampolsky, Claudio, additional, Yaremchuk, Michael J., additional, Yassari, Reza, additional, Yen, Chun-Po, additional, Yianni, John, additional, Yu, Alexander K., additional, Zager, Eric L., additional, Zanotti, Bruno, additional, Zenteno, Marco, additional, Zileli, Mehmet, additional, and Zouzias, Alexandros D., additional

Published
2012
Full Text
View/download PDF

99. MGMTpromoter methylation analysis for allocating combined CCNU / TMZ chemotherapy: Lessons learned from the CeTeG / NOA ‐09 trial

Author

Tzaridis, Theophilos, primary, Schäfer, Niklas, additional, Weller, Johannes, additional, Steinbach, Joachim‐Peter, additional, Schlegel, Uwe, additional, Seidel, Sabine, additional, Sabel, Michael, additional, Hau, Peter, additional, Seidel, Clemens, additional, Krex, Dietmar, additional, Goldbrunner, Roland, additional, Tonn, Jörg‐Christian, additional, Grauer, Oliver, additional, Kebir, Sied, additional, Schneider, Matthias, additional, Schaub, Christina, additional, Vatter, Hartmut, additional, Coch, Christoph, additional, Glas, Martin, additional, Fimmers, Rolf, additional, Pietsch, Torsten, additional, Reifenberger, Guido, additional, Herrlinger, Ulrich, additional, and Felsberg, Jörg, additional

Published
2020
Full Text
View/download PDF

100. BIOM-59. TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK?

Author

Gramatzki, Dorothee, primary, Felsberg, Jörg, additional, Hentschel, Bettina, additional, Wolter, Marietta, additional, Schackert, Gabriele, additional, Westphal, Manfred, additional, Regli, Luca, additional, Thon, Niklas, additional, Tatagiba, Marcos, additional, Wick, Wolfgang, additional, Schlegel, Uwe, additional, Krex, Dietmar, additional, Matschke, Jakob, additional, Roth, Patrick, additional, Suresh, Marian, additional, Kamp, Marcel, additional, Rushing, Elisabeth, additional, Pietsch, Torsten, additional, von Deimling, Andreas, additional, Sabel, Michael, additional, Loeffler, Markus, additional, Weller, Michael, additional, and Reifenberger, Guido, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results